FindTrial
Sign In

Inhaled Nitric Oxide in Adults with Congenital Heart Disease and Pulmonary Hypertension

Evaluation of Inhaled Nitric Oxide in Postoperative Patients with Congenital Heart Disease and Pulmonary Hypertension

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400091214
Enrollment
Unknown
Registered
2024-10-23
Start date
2024-02-04
Completion date
Unknown
Last updated
2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Heart Disease

Interventions

Inhaled Nitric Oxide Group:NA

Sponsors

Peking University International Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Age = 18 years; 2) Congenital heart disease combined with PH, according to the updated criteria of the latest 2022 European Pulmonary Hypertension Guideline, resting pulmonary artery pressure > 20 mmHg as determined by right heart catheterization; 3) Undergo and complete cardiac surgical treatment, with clinical assessment requiring treatment with inhaled nitric oxide (=6h).

Exclusion criteria

Exclusion criteria: 1) Significant risk of bleeding; 2) Confirmed diagnosis of high ferritinemia; 3) Incomplete hospital case system data, preventing data collection, analysis, and statistics.

Design outcomes

Primary

MeasureTime frame
Change in pulmonary artery pressure;—

Secondary

MeasureTime frame
Change in Oxygenation Index (PaO2/FiO2);Incidence of complications;—

Countries

China

Contacts

Public ContactRuofan Liu

Peking University International Hospital

liuruofan2024@126.com+86 188 1048 8857

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026